Long-term Results of Catheter Ablation for Irregular and Fast Heart Rhythms

Other criteria

• Atrial Fibrillation (AF) Cohort:; Inclusion Criteria (Patients must meet ALL of the following criteria):; Age ≥ 18 years; Diagnosed with atrial fibrillation (AF), including paroxysmal AF (PAF) and persistent AF (PsAF); Scheduled to undergo first-time catheter ablation for AF; Procedure to be performed using a 3D mapping system; Provision of signed written informed consent for study participation and willingness and ability to comply with all protocol-required follow-up assessments; Exclusion Criteria (Patients meeting ANY of the following criteria will be excluded):; Severe congenital heart disease (e.g., Tetralogy of Fallot, corrected transposition of the great arteries); AF secondary to a clearly reversible cause (e.g., hyperthyroidism, post-operative state, acute alcohol intoxication); Unstable angina pectoris or acute myocardial infarction (MI) within 30 days prior to enrollment/procedure; Severe active infection (e.g., septic shock, sepsis); Contraindications to anticoagulation therapy; Current participation in another interventional clinical trial that may confound the results of this study; Any other condition where, in the investigator's judgment, the patient is unsuitable for participation in this study
• Ventricular Tachycardia (VT) Cohort; Inclusion Criteria (Patients must meet ALL of the following criteria):; Age ≥ 18 years; Diagnosed with ventricular tachycardia (VT) associated with underlying structural heart disease, including:; Ischemic heart disease (e.g., prior MI, coronary artery disease); Non-ischemic cardiomyopathy (e.g., dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), hypertrophic cardiomyopathy (HCM)); Scheduled to undergo first-time catheter ablation for VT; Procedure to be performed using a 3D mapping system; Provision of signed written informed consent for study participation and willingness and ability to comply with all protocol-required follow-up assessments; Exclusion Criteria (Patients meeting ANY of the following criteria will be excluded):; VT due to a transient or reversible cause (e.g., acute myocardial ischemia, severe electrolyte imbalance); Idiopathic ventricular tachycardia (VT occurring in the absence of structural heart disease); Cardiac surgery within 60 days prior to the planned ablation procedure; Severe coagulopathy (e.g., platelet count < 50 x 10⁹/L, disseminated intravascular coagulation (DIC)); Severe heart failure with left ventricular ejection fraction (LVEF) < 20%; Severe active infection (e.g., septic shock, sepsis); Current participation in another interventional clinical trial that may confound the results of this study; Any other condition where, in the investigator's judgment, the patient is unsuitable for participation in this study